NetworkNewsBreaks – Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) Secures $115.1 Million in Underwritten Public Offering
Crinetics Pharmaceuticals (NASDAQ: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, has closed an underwritten public offering of 8,222,500 shares of its common stock, which includes an additional 1,072,500 shares per the full exercise of the over-allotment option granted to the underwriters. According to the update, Crinetics Pharmaceuticals secured approximately $115.1 million in gross proceeds, with each of the shares sold at the public offering price of $14.00. The company intends to use the proceeds to fund the development of paltusotine and its other research and…







